Evidence map›Paper›PMID 38746158›Full record

ArticlebioRxiv : the preprint server for biology2024

APOBEC3 mutagenesis drives therapy resistance in breast cancer.

Avantika Gupta, Andrea Gazzo, Pier Selenica, Anton Safonov, Fresia Pareja, Edaise M da Silva, David N Brown, Yingjie Zhu, Juber Patel, Juan Blanco-Heredia and 15 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Avantika GuptaORCID 0000-0002-8170-6720
Andrea Gazzo
Pier Selenica
Anton Safonov
Fresia Pareja
Edaise M da Silva
David N Brown
Yingjie Zhu
Juber Patel
Juan Blanco-Heredia
Bojana Stefanovska
Michael A Carpenter
Xin Pei
Denise Frosina
Achim A Jungbluth
Marc Ladanyi
Giuseppe Curigliano
Britta Weigelt
Nadeem Riaz
Simon N Powell
Pedram Razavi
Reuben S Harris
Jorge S Reis-Filho
Antonio Marra
Sarat Chandarlapaty

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Targeting Polθ to Overcome PARP Inhibitor Resistance in Homologous Recombination Deficient Breast CancerP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Sarat Chandarlapaty, Simon N. Powell · 2020 to 2026
$16.3M
Defining mechanisms of resistance to hormonal therapy in breast cancerR01CA234361 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHANDARLAPATY, SARAT, SOLIT, DAVID B. · 2019 to 2023
$2.0M
Defining the impact of mutant oncogene zygosityR01CA245069 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHANDARLAPATY, SARAT · 2020 to 2024
$2.0M
Implications and Vulnerabilities of APOBEC Mutagenesis in Breast CancerR01CA244812 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHANDARLAPATY, SARAT, HARRIS, REUBEN S · 2020 to 2020
$722k
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA247749NCI NIH HHS R01 CA234361NCI NIH HHS R01 CA245069
6 · The paper itself

Abstract

Acquired genetic alterations commonly drive resistance to endocrine and targeted therapies in metastatic breast cancer

Identifiers

PMID38746158
PMCPMC11092499

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.